Daclatasvir Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Daclatasvir is used along with another medication (sofosbuvir [Solvadi]) to treat a certain type of chronic hepatitis C (an ongoing viral infection that damages the liver). Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors.Daclatasvir Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Daclatasvir Nitroso CAS NO:NA chemically represented as Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1-nitroso-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate. Synchemia is the leading manufacturing and exporter of Daclatasvir Nitroso . We supply Daclatasvir Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0141907 |
| CAS No | NA |
| Mol.F. | C20H22N6O5 |
| Mol.Wt. | 426.4g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141908 |
| CAS No | NA |
| Mol.F. | C20H24N6O4 |
| Mol.Wt. | 412.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141909 |
| CAS No | NA |
| Mol.F. | C18H20N6O3 |
| Mol.Wt. | 368.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141910 |
| CAS No | NA |
| Mol.F. | C18H19N7O4 |
| Mol.Wt. | 397.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141911 |
| CAS No | NA |
| Mol.F. | C26H22FN3O2 |
| Mol.Wt. | 427.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141912 |
| CAS No | NA |
| Mol.F. | C33H33FN3O6 |
| Mol.Wt. | 586.6 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141913 |
| CAS No | NA |
| Mol.F. | C15H17N3O2 |
| Mol.Wt. | 271.3 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0141914 |
| CAS No | NA |
| Mol.F. | C16H21ClN4O2 |
| Mol.Wt. | 336.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141915 |
| CAS No | NA |
| Mol.F. | C16H21ClN4O |
| Mol.Wt. | 320.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141916 |
| CAS No | NA |
| Mol.F. | C16H20ClN3O3 |
| Mol.Wt. | 337.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141917 |
| CAS No | NA |
| Mol.F. | C16H20ClN5O3 |
| Mol.Wt. | 365.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141918 |
| CAS No | NA |
| Mol.F. | C18H25ClN4O3 |
| Mol.Wt. | 380.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141919 |
| CAS No | NA |
| Mol.F. | C16H21ClN4O |
| Mol.Wt. | 320.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141920 |
| CAS No | NA |
| Mol.F. | C14H16ClN3O2 |
| Mol.Wt. | 293.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141921 |
| CAS No | NA |
| Mol.F. | C18H25ClN4O5S |
| Mol.Wt. | 444.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141922 |
| CAS No | NA |
| Mol.F. | C20H27ClN4O3 |
| Mol.Wt. | 406.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |